(S (NP (JJ Monoclonal) (NNS antibodies)) (VP (VBP constitute) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (ADJP (RBS most) (JJ important)) (NNS strategies)))) (S (VP (TO to) (VP (VB treat) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NP (NNS cancers)) (PP (JJ such) (IN as) (NP (NP (JJ hematological) (NNS malignancies)) (CC and) (NP (JJ solid) (NNS tumors)))))))))))) (. .))
(S (PP (IN In) (NP (NN order) (S (VP (TO to) (VP (VB guarantee) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (DT those) (NNS preparations)) (VP (VBN prepared) (PP (IN at) (NP (NN hospital)))))))))))) (, ,) (NP (NN quality) (NN control)) (VP (VBZ has) (S (VP (TO to) (VP (VB be) (VP (VBN developed)))))) (. .))
(S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB explore) (NP (DT a) (ADJP (JJ noninvasive) (, ,) (JJ nondestructive) (, ,) (CC and) (JJ rapid)) (JJ analytical) (NN method)) (S (VP (TO to) (VP (VB ensure) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (DT the) (JJ final) (NN preparation)))) (PP (IN without) (S (VP (VBG causing) (NP (NP (DT any) (NN delay)) (PP (IN in) (NP (DT the) (NN process)))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (NP (CD four) (NNS mAbs)) (-LRB- -LRB-) (NP (NNP Inlfiximab) (, ,) (NNP Bevacizumab) (, ,) (NNP Ramucirumab) (CC and) (NNP Rituximab)) (-RRB- -RRB-)) (VP (VBN diluted) (PP (IN at) (NP (NP (JJ therapeutic) (NN concentration)) (PP (IN in) (NP (NML (NN chloride) (NN sodium)) (NML (ADJP (NP (CD 0.9) (NN %)) (VBG using)) (NNP Raman) (NN spectroscopy))))))))) (. .))
(S (S (VP (TO To) (VP (VB reduce) (NP (NP (DT the) (NN prediction) (NNS errors)) (VP (VBN obtained) (PP (IN with) (NP (NP (JJ traditional) (JJ chemometric) (NNS data)) (NP (NN analysis))))))))) (, ,) (NP (PRP we)) (VP (VBD explored) (NP (NP (DT a) (ADJP (NN data) (HYPH -) (VBN driven)) (NN approach)) (VP (VBG using) (NP (NP (JJ statistical) (NML (NN machine) (NN learning)) (NNS methods)) (SBAR (WHADVP (WRB where)) (S (NP (ADJP (JJ preprocessing) (CC and) (JJ predictive)) (NNS models)) (VP (VBP are) (ADVP (RB jointly)) (VP (VBN optimized))))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBD prepared) (NP (DT a) (NML (NN data) (NNS analytics)) (NN workflow))) (CC and) (VP (VBD submitted) (NP (DT the) (NN problem)) (PP (IN to) (NP (NP (DT a) (JJ collaborative) (NML (NN data) (NN challenge)) (NN platform)) (VP (VBN called) (NP (NP (NNP Rapid) (NNP Analytics)) (CC and) (NP (NNP Model) (NNP Prototyping))))))) (PRN (-LRB- -LRB-) (NP (NN RAMP)) (-RRB- -RRB-))) (. .))
(S (NP (DT This)) (VP (VBD allowed) (S (VP (TO to) (VP (VB use) (NP (NP (NNS solutions)) (PP (IN from) (NP (QP (RB about) (CD 300)) (NNS data) (NNS scientists)))) (PP (IN during) (NP (NP (CD five) (NNS days)) (PP (IN of) (NP (JJ collaborative) (NN work))))))))) (. .))
(S (NP (NP (DT The) (NN prediction)) (PP (IN of) (NP (DT the) (CD four) (NNS mAbs) (NNS samples)))) (VP (VBD was) (ADVP (RB considerably)) (VP (VBN improved) (PP (IN with) (NP (NP (DT a) (NN misclassification) (NN rate)) (CC and) (NP (NP (DT the) (JJ mean) (NN error) (NN rate)) (PP (IN of) (NP (QP (CD 0.8) (NN %) (CC and) (CD 4) (NN %))))))) (, ,) (ADVP (RB respectively)))) (. .))
